Cardiac troponin I remains the preferred cardiac marker for AMI diagnosis, according to guidelines published by the European Society of Cardiology (ESC), the American College of Cardiology (ACC), and the American Heart Association (AHA).[21,22] Therefore, we used cTnI as a control group to evaluate the clinical value of copeptin combined hs-cTnT in the diagnosis of early acute myocardial infarction. This evidence concerns the gene TNNT2 and myocardial infarction.